Clinical Trial Detail

NCT ID NCT02112032
Title Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hassane M. Zarour, MD
Indications

melanoma

Therapies

Peginterferon alfa-2b + Pembrolizumab

Age Groups: adult

No variant requirements are available.